Media milling process optimization for manufacture of drug nanoparticles using design of experiments (DOE)

Drug Development and Industrial Pharmacy

Volumn 41, Issue 1, 2015, Pages 124-130

  Nekkanti, Vijaykumar ^a   Marwah, Ashwani ^b   Pillai, Raviraj ^b  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Bead milling; Central composite design; Design of experiments; Process optimization; QbD

Indexed keywords

FENOFIBRATE; NANOPARTICLE;

ARTICLE; BEAD MILLING PROCESS; DRUG MANUFACTURE; EXPERIMENTAL DESIGN; MEASUREMENT REPEATABILITY; PARTICLE SIZE; PROCESS OPTIMIZATION; RELIABILITY; REPRODUCIBILITY; RESPONSE VARIABLE; CHEMISTRY; MEDICINAL CHEMISTRY; PROCEDURES; STANDARDS; SYNTHESIS; TOTAL QUALITY MANAGEMENT;

CHEMISTRY, PHARMACEUTICAL; FENOFIBRATE; NANOPARTICLES; PARTICLE SIZE; QUALITY IMPROVEMENT;

EID: 84918840704     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.850709     Document Type: Article

References (15)

1. Fisher RA. The design of experiments. London: Oliver and Boyd; 1935:35-8.
2. Nekkanti V, Muniyappan T, Karatgi P, et al. Spray-drying process optimization for manufacture of drug-cyclodextrin complex powder using design of experiments. Drug Dev Ind Pharm 2009;35:1219-29.
3. Guidance for industry, quality system approach to pharmaceutical CGMP regulations. 2006. Available from: http://www.fda.gov/downloads/Drugs/../Guidances/UCM070337.pdf [last accessed 27 Aug 2013].
4. Billon A, Bataille B, Cassanas G, Jacob M. Development of spray-dried acetaminophen microparticles using experimental designs. Int J Pharm 2000;203:159-68.
5. Vaithiyalingam S, Khan MA. Optimization and characterization of controlled release multi-particulate beads formulated with a customized cellulose acetate butyrate dispersion. Int J Pharm 2002;234:179-93.
6. Tewa-Tagne P, Briançon S, Fessi H. Spray-dried microparticles containing polymeric nanocapsules: formulation aspects, liquid phase interactions and particles characteristics. Int J Pharm 2006; 325:63-74.
7. Dévay A, Mayer K, Pál S, Antal I. Investigation on drug dissolution and particle characteristics of pellets related to manufacturing process variables of high-shear granulation. J Biochem Biophys Methods 2006;69:197-205.
8. Nekkanti V, Karatgi P, Joshi M, Pillai R. Developing nanoparticle formulations or poorly soluble drugs. Phar Tech Eur 2008;11:24-8.
9. Verma S, Lan Y, Gokhale R, Burgess DJ. Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm 2009;377:185-98.
10. Zidan AS, Sammour OA, Hammad MA, et al. Quality by design: understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box-Behnken design and desirability function. Int J Pharm 2007;332:55-63.
11. Singare DS, Marella S, Gowthamrajan K, et al. Optimization of formulation and process variable of nanosuspension: an industrial perspective. Int J Pharm 2010;402:213-20.
12. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003;18:113-20.
13. Box GE, Hunter WG, Hunter JS. Statistics for experimenters: an introduction to design, data analysis, and model building. New York: Wiley; 1978:313-19.
14. Liberman H, Rieger M, Banker G. Pharmaceutical dosage forms: disperse systems. New York: Mercel Dekker; 1989:438-64.
15. Derringer GC. A balancing act-optimizing a products properties. Qual Prog 1994;27:51-8.